Empagliflozin for No-reflow Phenomenon in PCI for STEMI
A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 162 participants.
Also called NCT06342141
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose prevention
- Phase
- Phase 2
- Enrolled
- 162 participants
- Registry
-
NCT06342141
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- Mexico
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06342141. Randomized; triple masking; primary purpose prevention. Start 2024-08-22 (actual); primary completion 2026-03-15 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Empagliflozin for No-reflow Phenomenon in PCI for STEMI
- Acronym
- EMPA-PCI
- Condition
- STEMI
- Condition
- No-Reflow Phenomenon
- Intervention (Drug)
- Empagliflozin 25 milgrams (Mg)
- Intervention (Drug)
- Empagliflozin 10 Mg
- Lead sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez
Record details
- Record id
cardio:ct-nct06342141- Content hash
797710ac89692eee11feacf31db96e5d2a8113d01da92b8948bde3bb10945fc0